Analysts Set Pfizer Inc. (NYSE:PFE) PT at $33.58

Pfizer Inc. (NYSE:PFE - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the firm, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $33.58.

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They set a "neutral" rating and a $30.00 price target on the stock. Daiwa Capital Markets raised shares of Pfizer from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a "neutral" rating in a research note on Wednesday, July 31st.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company's stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.06% of the company's stock.

Hedge Funds Weigh In On Pfizer

Institutional investors and hedge funds have recently bought and sold shares of the business. FAS Wealth Partners Inc. boosted its stake in shares of Pfizer by 1.3% during the 2nd quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company's stock valued at $736,000 after buying an additional 342 shares during the period. Sachetta LLC grew its stake in Pfizer by 7.3% in the second quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company's stock valued at $140,000 after purchasing an additional 342 shares in the last quarter. Wells Trecaso Financial Group LLC raised its stake in shares of Pfizer by 2.5% during the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock worth $416,000 after purchasing an additional 350 shares in the last quarter. Ironvine Capital Partners LLC lifted its holdings in shares of Pfizer by 2.1% during the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company's stock valued at $470,000 after buying an additional 353 shares during the last quarter. Finally, Secure Asset Management LLC grew its stake in shares of Pfizer by 0.6% in the 2nd quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company's stock valued at $1,632,000 after buying an additional 353 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE traded down $0.41 during trading hours on Thursday, hitting $26.31. The company had a trading volume of 23,688,709 shares, compared to its average volume of 37,713,520. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $149.10 billion, a P/E ratio of 35.74, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. Pfizer has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The business has a fifty day simple moving average of $28.76 and a 200-day simple moving average of $28.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company's quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. Equities analysts predict that Pfizer will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.39%. Pfizer's payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.